Modulation of ERK5 Activity as a Therapeutic Anti-Cancer Strategy. (2023)

First Author: Miller DC
Attributed to:  Discovery of ERK5 inhibitors for biomarker-driven clinical evaluation in cancer funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1021/acs.jmedchem.3c00072

PubMed Identifier: 37002872

Publication URI: http://europepmc.org/abstract/MED/37002872

Type: Journal Article/Review

Volume: 66

Parent Publication: Journal of medicinal chemistry

Issue: 7

ISSN: 0022-2623